BRIEF published on 03/04/2024 at 08:05, 2 years ago Defence Therapeutics Gains Significant US Patent for Cancer-Killing AccuTOX® Technology Cancer Treatment Defence Therapeutics AccuTOX® Technology US Patent Antibody-drug Conjugates
PRESS RELEASE published on 03/04/2024 at 08:00, 2 years ago DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY Defence Therapeutics Inc. is granted a broad U.S. patent for its innovative cancer-killing AccuTOX technology, potentially providing market exclusivity until late 2042 Defence Therapeutics Inc. Broad U.S. Patent AccuTOX Technology Cancer-killing Market Exclusivity
PRESS RELEASE published on 11/07/2023 at 08:00, 2 years 4 months ago DEFENCE THERAPEUTICS KEY PLATFORM PATENT ACCEPTED BROADLY COVERING VACCINE TECHNOLOGY
PRESS RELEASE published on 10/25/2023 at 08:00, 2 years 4 months ago DEFENCE’S ACCUTOX® AND ANTIGEN CROSS-PRESENTATION: DISCOVERY LEADS TOWARDS THE DEVELOPMENT OF A GROUDNBREAKING PLATFORM
PRESS RELEASE published on 10/18/2023 at 08:00, 2 years 4 months ago Defence Therapeutics Inc.: DEFENCE’S NOVEL ACCUTOXTM CONTINUES TO SURPRISE ON RESULTS AGAINST CANCER
PRESS RELEASE published on 10/17/2023 at 08:00, 2 years 5 months ago Defence Therapeutics Inc.: DELIVERY OF ENCAPSULATED ACCUTOXTM-CHITOSAN NANOPARTICLES TRIGGERS COMPLETE TUMOR REGRESSION IN ANIMALS WITH PRE-ESTABSLIHED SOLID LYMPHOMA
PRESS RELEASE published on 10/10/2023 at 08:00, 2 years 5 months ago DEFENCE ANNOUNCES PEER-REVIEWED PUBLICATION OF ITS PRECLINICAL DATA ON ACCUM® AS AN ANTI-CANCER MOLECULE IN THE JOURNAL OF CANCER SCIENCE
PRESS RELEASE published on 09/25/2023 at 08:00, 2 years 5 months ago DEFENCE’S ACCUM®-mRNA LIPID NANOPARTICLES ELICIT ANTIBODY RESPONSE 2X STRONGER THAN STANDARD mRNA VACCINES
PRESS RELEASE published on 09/12/2023 at 08:00, 2 years 6 months ago DEFENCE’S BROAD AND VERSATILE ACCUM® TECHNOLOGY PLATFORM FOCUS ON CANCER THERAPEUTICS
PRESS RELEASE published on 09/05/2023 at 08:00, 2 years 6 months ago DEFENCE’S INNOVATIVE THERAPEUTICS FEATURED ON VIEWPOINT WITH DENNIS QUAID
Published on 03/17/2026 at 21:30, 54 minutes ago Rainy Mountain Announces Appointment of Colton Griffith to Board of Directors
Published on 03/17/2026 at 13:30, 8 hours 54 minutes ago Hillcrest Energy Technologies Confirms ZVS PCS1000 Prototype on Track for June 2026
Published on 03/17/2026 at 13:30, 8 hours 54 minutes ago Namibia Critical Metals Welcomes Toyota Tsusho as Strategic Partner in the Lofdal Heavy Rare Earths Project
Published on 03/17/2026 at 13:00, 9 hours 24 minutes ago Avant Brands Announces Strategic Realignment of European Operations and Reclaims BLK MKT Brand Rights in Germany and Switzerland
Published on 03/17/2026 at 21:21, 1 hour 3 minutes ago KION GROUP AG successfully places a bond of € 500 million
Published on 03/17/2026 at 20:55, 1 hour 29 minutes ago EQS-Adhoc: thyssenkrupp nucera lowers its sales and EBIT outlook for the Group and the gH2 segment for FY 2025/26 due to higher project costs
Published on 03/17/2026 at 17:58, 4 hours 26 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/17/2026 at 07:00, 15 hours 24 minutes ago Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day 4 hours ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day 4 hours ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day 4 hours ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026
